Squarepoint
RLMD icon

Squarepoint’s Relmada Therapeutics RLMD Stock Holding History

Squarepoint’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$441K Sell
63,426
-74,807
-54% -$354K ﹤0.01% 3405
2025
Q4 		$668K Buy
+138,233
New +$463K ﹤0.01% 2964
2024
Q3 		– Sell
-35,425
Closed -$106K – 4608
2024
Q2 		$106K Sell
35,425
-43,588
-55% -$158K ﹤0.01% 3786
2024
Q1 		$367K Buy
79,013
+5,579
+8% +$26.9K ﹤0.01% 3256
2023
Q4 		$304K Buy
73,434
+40,337
+122% +$119K ﹤0.01% 3350
2023
Q3 		$99.3K Sell
33,097
-45,923
-58% -$136K ﹤0.01% 3558
2023
Q2 		$194K Buy
+79,020
New +$218K ﹤0.01% 3232
2023
Q1 		– Sell
-35,281
Closed -$123K – 3724
2022
Q4 		$123K Buy
+35,281
New +$310K ﹤0.01% 2931
2021
Q1 		– Sell
-7,130
Closed -$229K – 3533
2020
Q4 		$229K Buy
+7,130
New +$245K ﹤0.01% 2419
2020
Q3 		– Sell
-8,106
Closed -$363K – 2786
2020
Q2 		$363K Buy
+8,106
New +$343K 0.01% 1483
2020
Q1 		– Sell
-8,918
Closed -$348K – 2404
2019
Q4 		$348K Buy
+8,918
New +$271K ﹤0.01% 1965

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Squarepoint's RLMD Position: Q1 2026 in Review

Squarepoint reduced its Relmada Therapeutics (RLMD) stake by 54% in Q1 2026, selling an estimated $354K and leaving 63,426 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Squarepoint first reported a position in RLMD in Q4 2019 and has held it in 11 quarters since. The position peaked at $668K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Squarepoint held 63,426 shares of Relmada Therapeutics worth $441K as of Q1 2026.
  • Squarepoint sold 74,807 Relmada Therapeutics shares in Q1 2026, an estimated $354K.
  • Relmada Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3405 holding.
  • Squarepoint first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 11 quarters since.
  • Squarepoint's Relmada Therapeutics position peaked at $668K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.